chronic obstructive pulmonary disease dupixent news

Dupixent, sBLA and Regeneron

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Daily · 2d

Sanofi, Regeneron Dupixent sBLA accepted for USFDA review for chronic spontaneous urticaria

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA)

Pharmabiz · 1d

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin

Business Insider · 4d

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

MarketWatch · 4d

Regeneron, Sanofi Get New FDA Review of Dupixent for CSU

Regeneron Pharmaceuticals and Sanofi said the U.S. Food and Drug Administration has accepted their resubmitted application seeking expanded approval of the blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic spontaneous urticaria,

Hosted on MSN17h

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

prurigo nodularis and chronic obstructive pulmonary disease. Dupixent is being jointly marketed by Regeneron and ...

Benzinga.com6d

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new ...

Managed Healthcare Executive4d

FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

ktiv7d

Healthbeat 4: What is chronic obstructive pulmonary disease and how do you prevent it?

SIOUX CITY (KTIV) - The World Health Organization says chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. COPD is ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results